Literature DB >> 17527113

Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis.

Rosita M Shah1, Sergio Jimenez, Richard Wechsler.   

Abstract

Despite little supportive evidence, ground-glass opacity at high-resolution computed tomography, without other signs of fibrosis, has been equated with potentially reversible disease, and in systemic sclerosis, frequently prompts aggressive anti-inflammatory treatment to prevent pulmonary fibrosis. Our study evaluates ground-glass opacity on sequential high-resolution computed tomography in 41 patients with systemic sclerosis over a mean follow-up period of 27 months (r6 to 60 mo). Ground-glass opacity was the most common imaging finding, present in 66%, and usually associated with other signs of interstitial disease, including nonfibrotic interstitial opacities in 27% and fibrotic interstitial opacities in 32%. Improvement was only documented in 2(5%) patients with ground glass and nonfibrotic interstitial opacities. In systemic sclerosis, ground-glass opacity is most commonly associated with irreversible disease. Disease progression or improvement could not be predicted by the presence of ground-glass opacity.

Entities:  

Mesh:

Year:  2007        PMID: 17527113     DOI: 10.1097/01.rti.0000213572.16904.40

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  17 in total

1.  Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.

Authors:  Jonathan G Goldin; Grace Hyun J Kim; Chi-Hong Tseng; Elizabeth Volkmann; Daniel Furst; Philip Clements; Matt Brown; Michael Roth; Dinesh Khanna; Donald P Tashkin
Journal:  Ann Am Thorac Soc       Date:  2018-11

2.  The race against time to disclose lung inflammation in interstitial lung disease in systemic sclerosis: is PET scan the winning solution?

Authors:  Silvia Bellando-Randone; Marco Matucci-Cerinic
Journal:  Rheumatology (Oxford)       Date:  2020-06-01       Impact factor: 7.580

3.  [Pulmonary manifestations of connective tissue diseases].

Authors:  B Rehbock
Journal:  Radiologe       Date:  2015-03       Impact factor: 0.635

4.  PET/CT and inflammatory mediators in systemic sclerosis-associated interstitial lung disease.

Authors:  Andréa L Bastos; Gilda A Ferreira; Marcelo Mamede; Eliane V Mancuzo; Mauro M Teixeira; Flávia P S T Santos; Cid S Ferreira; Ricardo A Correa
Journal:  J Bras Pneumol       Date:  2022-06-06       Impact factor: 2.800

Review 5.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

Review 6.  Imaging lung disease in systemic sclerosis.

Authors:  Diane Strollo; Jonathan Goldin
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

7.  Pulmonary ground-glass nodules diagnosis: mean change rate of peak CT number as a discriminative factor of pathology during a follow-up.

Authors:  Mingzheng Peng; Zhao Li; Haiyang Hu; Sida Liu; Binbin Xu; Wenzhuo Zhu; Yudong Han; Liwen Xiong; Qiang Lin
Journal:  Br J Radiol       Date:  2015-11-12       Impact factor: 3.039

Review 8.  The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients.

Authors:  Barbara Ruaro; Marco Confalonieri; Francesco Salton; Barbara Wade; Elisa Baratella; Pietro Geri; Paola Confalonieri; Metka Kodric; Marco Biolo; Cosimo Bruni
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-23

9.  Significance of various pulmonary and extrapulmonary abnormalities on HRCT of the chest in scleroderma lung.

Authors:  Anoop Kumar Pandey; Pearce Wilcox; Julie O' Brien; Jennifer Ellis; Jacquie Brown; Jonathon Leipsic
Journal:  Indian J Radiol Imaging       Date:  2013-10

Review 10.  [Pulmonary manifestations in collagen vascular diseases].

Authors:  M N A Vogel; M Kreuter; H-U Kauczor; C-P Heußel
Journal:  Radiologe       Date:  2016-10       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.